FAM
CBIO

Fred Alger Management’s Crescent Biopharma CBIO Stock Holding History

Fred Alger Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-550
Closed -$125K – 535
2020
Q1 		$125K Sell
550
-50
-8% -$19.1K ﹤0.01% 405
2019
Q4 		$317K Hold
600
– – ﹤0.01% 402
2019
Q3 		$259K Buy
600
+200
+50% +$129K ﹤0.01% 397
2019
Q2 		$477K Buy
+400
New +$478K ﹤0.01% 384
2018
Q2 		– Sell
-70
Closed -$114K – 558
2018
Q1 		$114K Buy
70
+50
+250% +$104K ﹤0.01% 404
2017
Q4 		$34K Buy
+20
New +$26.4K ﹤0.01% 442

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fred Alger Management's CBIO Position: Q2 2020 in Review

Fred Alger Management sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 550 shares — an estimated $125K sold.

Fred Alger Management first reported a position in CBIO in Q4 2017 and held it in 6 quarters. The position peaked at $477K in Q2 2019. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Fred Alger Management reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • Fred Alger Management sold 550 Crescent Biopharma shares in Q2 2020, an estimated $125K.
  • Fred Alger Management first reported a position in Crescent Biopharma in Q4 2017 and held it in 6 quarters.
  • Fred Alger Management's Crescent Biopharma position peaked at $477K in Q2 2019.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Fred Alger Management's 13F filing for Q2 2020, filed 14 Aug 2020.